Table 3 Antibiotic susceptibility profiles of the Gram-negative MDR ESKAPEE bacterial pathogens
Antimicrobial agent | Acinetobacter baumannii, n = 23 (%) | Klebsiella pneumoniae, n = 22 (%) | Enterobacter cloacae, n = 19 (%) | Escherichia coli, n = 5, (%) | Pseudomonas aeruginosa, n = 2 (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Â | NS | S | NS | S | NS | S | NS | S | NS | S |
Piperacillin | 23 (100) | 0 | 22 (100) | 0 | 18 (94.7) | 1 (5.3) | 4 (80.0) | 1 (20.0) | 1 (50) | 1 (50) |
Ticarcillin-Clavulanic Acid | 23 (100) | 0 | 18 (81.8) | 4 (18.2) | 18 (94.7) | 1 (5.2) | 5 (100) | 0 | 2 (100) | 0 |
Cefuroxime | nd | nd | 22 (100) | 0 | 19 (100) | 0 | 4 (80.0) | 1 (20.0) | nd | nd |
Cefixime | nd | nd | 22 (100) | 0 | 19 (100) | 0 | 4 (80.0) | 1 (20.0) | nd | nd |
Ceftriaxone | 23 (100) | 0 | 22 (100) | 0 | 19 (100) | 0 | 4 (80.0) | 1 (20.0) | nd | nd |
Cefepime | 23 (100) | 0 | 22 (100) | 0 | 19 (100) | 0 | 3 (60.0) | 2 (40.0) | nd | nd |
Aztreonam | nd | nd | 22 (100) | 0 | 19 (100) | 0 | 3 (60.0) | 2 (40.0) | nd | nd |
Meropenem | 23 (100) | 0 | 5 (22.7) | 17 (77.3) | 0 | 19 (100) | 0 | 5 (100) | 2 (100) | 0 |
Moxifloxacin | nd | nd | 11 (50.0) | 11 (50.0) | 3 (15.8) | 16 (84.2) | 2 (40.0) | 3 (60.0) | 0 | 2 (100) |
Levofloxacin | 6 (26.1) | 17 (73.9) | 10 (45.5) | 12 (54.5) | 3 (15.8) | 16 (84.2) | 2 (40.0) | 3 (60.0) | nd | nd |
Tetracycline | 12 (52.2) | 11 (47.8) | 14 (63.6) | 8 (36.4) | 16 (84.2) | 3 (15.8) | 3 (60.0) | 2 (40.0) | 2 (100) | 0 |
Minocycline | 1 (4.3) | 22 (95.7) | 14 (63.6) | 8 (36.4) | 15 (78.9) | 4 (21.1) | 4 (80.0) | 1 (20.0) | 0 | 2 (100) |
Tigecycline | 2 (8.7) | 21 (91.3) | nd | nd | 0 | 19 (100) | 0 | 5 (100) | 2 (100) | 0 |
Chloramphenicol | nd | nd | 13 (59.1) | 9 (40.9) | 13 (68.4) | 6 (31.6) | 2 (40.0) | 3 (60.0) | nd | nd |
Colistin | 0 | 23 (100) | 0 | 22 (100) | 1/ (5.3) | 18 (94.7) | 0 | 5 (100) | 0 | 2 (100) |
Trimethoprim | nd | nd | 21 (95.5) | 1 (0.5) | 15 (78.9) | 4 (21.1) | 5 (100) | 0 | nd | nd |